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Advances in Stroke 2007
Introduction
Marc Fisher, MD
The annual update of a broad range of topics related tocerebrovascular diseases encompassed by the designated
sections of Stroke is a widely appreciated feature. The current
update was expanded from previous years to now include the
new section of Population Studies, and additionally the basic
science editors invited 2 updates with relevance to both basic
scientists and clinicians. The editors hope that the readership
will continue to value these brief but insightful updates and
provide feedback as to how to potentially improve the
material encompassed in the annual Advances section. We
thank the section editors and the basic science contributors
for their efforts.
In the genetics area, many important studies appeared
using genome-wide associations with a variety of complex
medical disorders. However, such a study of ischemic stroke
did not demonstrate that a single locus of main effect could
be determined. Genetic associations of single nucleotide
polymorphisms are also becoming increasingly common. We
can anticipate further studies of both types in helping to
elucidate genetic contributions to a variety of cerebrovascular
disorders.
Acute stroke therapies had another disappointing year with
failure of the neuroprotective drug NXY-059 in a second,
large phase III trial reported initially in late 2006 and in more
detail subsequently. Additionally, the novel thrombolytic
agent, desmoteplase, that had initially shown promise in 2
very small early phase II trials did not demonstrate benefit in
a larger study presented at the 2007 European Stroke Con-
ference. The reasons for this failure remain obscure and may
be clarified after detailed publication of the trial results.
The stroke prevention area was a therapeutic bright spot in
comparison to the predominantly gloomy results from acute
therapy trials. A trial of oral anticoagulation in elderly
nonvavular atrial fibrillation patients demonstrated that war-
farin was superior to aspirin with no increase in serious
bleeding side effects. A study from the United Kingdom of
urgent outpatient clinical assessment after transient ischemic
attack revealed that this approach substantially reduced stroke
risk as compared with routine evaluation by primary care
physicians. The use of the ABCD2 scoring scale for identify-
ing low and high risk transient ischemic attack patients was
confirmed, and this approach will likely prove useful in future
acute intervention studies after transient ischemic attack.
An important advance in the critical care management of
ischemic stroke patients in 2007 was the publication of the
combined evaluation of 3 small hemicraniectomy trials for
patients with malignant middle cerebral artery infarction. The
pooled analysis demonstrated a very substantial benefit for
this surgical approach as compared with standard medical
therapy for improving survival without an increase in depen-
dency. The restricted nature of the patient population studied
leaves many unanswered questions that will hopefully be
addressed by future trials. A disappointment in 2007 was the
failure of recombinant factor VII to improve outcome in
patients with intracerebral hemorrhage, despite a beneficial
effect on hemorrhage growth in a phase III trial. Subgroup
analysis of the study suggested that a select group may benefit,
but it is unclear whether further trials are forthcoming.
Healthcare policies continue to impact the care of cerebro-
vascular patients. Proposals for improving care were provided
by several national and international groups, along with new
and updated guidelines. The utility of stroke units was
confirmed and more widespread availability should be en-
couraged. The use of predictive modeling and enhancement
of quality improvement are other areas that should lead to
improved care.
In 2007 more information appeared about interventional
procedures for cerebrovascular disorders. Several important
studies of carotid artery stenting were published, but a
definitive comparison with endarterectomy remains lacking.
A stent for intracranial atherosclerosis was approved for use
by the FDA, and registry data suggest efficacy in reducing
stenosis with a reasonable complication rate.
Imaging of the ischemic penumbra with diffusion/perfu-
sion MRI and perfusion CT was evaluated in several publi-
cations. Case series suggest that such penumbral imaging
with MRI may be useful for selection of patients for
thrombolysis beyond 3 hours. A direct comparison of CT and
MRI penumbral imaging remains lacking, but both were
performed in the unsuccessful DIAS-II study of desmote-
plase, so information about comparable use should be forth-
coming. Multimodal MRI studies may also be useful in
predicting hemorrhagic risk with thrombolysis, but larger
confirmatory studies are needed.
The area of brain recovery and rehabilitation was heartened
by the reports that widely available fibroblasts can be used to
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produce multipotential embryonic stem cells. Although this is
an important advance, the potential of any type of stem cells
to enhance stroke recovery remains unproven. The beneficial
effects of stem cells may be related primarily to related
growth factors and cytokines, some of which are currently
under investigation as recovery enhancing agents. Imaging is
also of increasing use in relationship to stroke recovery, and
functional MRI and PET studies are being used to assess
recovery enhancing therapies. Preliminary interesting studies
of transcranial magnetic stimulation and local electrical
stimulation of muscles suggest that larger studies are
warranted.
The relationship of vascular disorders to dementia contin-
ues to be strengthened by newer studies. The risk of dementia
was reported to be increased 4-fold in patients with subcor-
tical infarcts. Cortical microinfarcts and microbleeds were
also shown to be associated with cognitive decline. A study of
galantamine in patients with probable vascular dementia
demonstrated that this cholinesterase inhibitor improved cog-
nition and executive function but did not improve activities of
daily living. As in other areas, imaging advances are helping
to assess patients with vascular cognitive impairment, and the
most interesting imaging modalities appear to be diffusion
tensor imaging and fractional anisotropy.
The 3 new contributions to the Advances in Stroke for
2007 include the new section, Population Studies, and 2
translation-related contributions. Population-related studies
indicated an increase in stroke hospitalization for 45- to
54-year-olds over the past 2 decades and a general increase in
inflation-adjusted cost for stroke-related diagnoses. Links
between air pollution, the metabolic syndrome, socioeco-
nomic status and stroke were enhanced by other studies.
Understanding of the mechanisms of neuronal death in
relationship to ischemia continued to evolve in 2007. The
important contributions of PARP1 activation and apoptosis-
inducing factor release as mediators of programmed cell
death became clearer. The role of mitochondrial death-
inducing signals such as BNIP3 also was clarified. Stress
induction of the endoplasmic reticulum, leading to autophagy
may also be an important mediator of ischemia-related cell
death. Translating enhanced basic understanding of ischemia-
related brain tissue injury into potential novel therapies is an
increasingly important endeavor. High-flow 100% normo-
baric hyperoxia prolongs penumbral survival in animals and
appears to extend the time window for reperfusion therapy.
One small feasibility study of this therapeutic approach
demonstrated safety and possible efficacy. Other gases, such
as hydrogen, helium and xenon, also demonstrate efficacy in
animal models. Laser light energy may improve stroke
outcome, and ultrasound energy may enhance clot dissolution
by tissue plasminogen activator.
As has been typical in the cerebrovascular arena, 2007 was
marked by many advances and disappointing clinical trial
failures, but the effort to move the field forward continues
unabated and with increasing energy, resources and
manpower.
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